论文部分内容阅读
创新药不能进入国家医保目录,不仅给患者带来沉重的经济压力,对于制药企业来说也是难以逾越的关卡。“孙副省长,最近我们在山东碰到一件很不可思议、也很难理解的事:正在进行的通过政府采购将部分医保目录外抗肿瘤靶向药纳入山东省职工大病保险和居民大病保险补偿范围的项目遴选中,入围的全是进口药,像我们这样自主研发的1.1类靶向抗癌药连进入谈判的机会都没有,很让人费解。”9月8日,国家“千人计划”专家、浙江贝达药业股份有限公司(下称“贝达药业”)董事长丁列明
Innovative drugs can not enter the national health insurance directory, not only to patients with heavy economic pressure, for the pharmaceutical companies is insurmountable level. “Vice Governor Sun, recently we encountered an incredible and difficult thing to understand in Shandong: Ongoing government procurement of some of the anti-cancer targeted drugs out of the medical insurance catalog will be included in the Shandong Province workers ’illness insurance and residents’ illness Insurance compensation range of projects in the selection, the finalists are all imported drugs, such as our self-developed 1.1 class anti-cancer drugs targeted even enter the negotiations have no chance, it is puzzling. ”“ September 8, the national ”Thousands plan“ expert, Zhejiang Beida Pharmaceutical Co., Ltd. (hereinafter referred to as ”Beida Pharmaceutical ") Ding Liuming